A Retrospective Real-World Study Based on RATIONALE-307
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
About this trial
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
Eligibility criteria
Qualifiers
Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Disqualifiers
Patients who had a documented death before study completion in the RATIONALE-307 trial
Trial design
Treatments tested in this trial
- No intervention
Treatment groups
109 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov